JP2023512657A5 - - Google Patents

Info

Publication number
JP2023512657A5
JP2023512657A5 JP2022545359A JP2022545359A JP2023512657A5 JP 2023512657 A5 JP2023512657 A5 JP 2023512657A5 JP 2022545359 A JP2022545359 A JP 2022545359A JP 2022545359 A JP2022545359 A JP 2022545359A JP 2023512657 A5 JP2023512657 A5 JP 2023512657A5
Authority
JP
Japan
Prior art keywords
glycine
methionine
seq
approximately
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022545359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512657A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016604 external-priority patent/WO2021158783A1/en
Publication of JP2023512657A publication Critical patent/JP2023512657A/ja
Publication of JP2023512657A5 publication Critical patent/JP2023512657A5/ja
Pending legal-status Critical Current

Links

JP2022545359A 2020-02-05 2021-02-04 Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法 Pending JP2023512657A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970554P 2020-02-05 2020-02-05
US62/970,554 2020-02-05
PCT/US2021/016604 WO2021158783A1 (en) 2020-02-05 2021-02-04 Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells

Publications (2)

Publication Number Publication Date
JP2023512657A JP2023512657A (ja) 2023-03-28
JP2023512657A5 true JP2023512657A5 (cg-RX-API-DMAC7.html) 2024-02-14

Family

ID=74870877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545359A Pending JP2023512657A (ja) 2020-02-05 2021-02-04 Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法

Country Status (6)

Country Link
US (1) US20230210952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100045A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023512657A (cg-RX-API-DMAC7.html)
KR (1) KR20220137630A (cg-RX-API-DMAC7.html)
AU (1) AU2021217373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021158783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146948A1 (en) * 2019-09-04 2021-03-11 Young Chul Sung Method for increasing lymphocyte count by using il-7 fusion protein in tumors
WO2025176860A1 (en) 2024-02-23 2025-08-28 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Dual chimeric antigen receptor construct targeting cea and epcam

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
DK0482076T3 (da) 1989-07-14 1995-07-17 American Cyanamid Co Stabile vaccinepræparater indeholdende interleukiner
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6749847B2 (en) 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US20050054054A1 (en) 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
HK1256149A1 (zh) 2015-06-11 2019-09-13 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US20190358258A1 (en) 2015-10-09 2019-11-28 Robert J. Deans Methods for enhancing proliferation of t regulatory cells
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
JP6971986B2 (ja) * 2016-04-01 2021-11-24 アプセト ゲーエムベーハー アンド ツェーオー.カーゲー 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
US11702459B2 (en) 2017-03-07 2023-07-18 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
GB201800298D0 (en) 2018-01-09 2018-02-21 Autolus Ltd Method
AU2019215031C1 (en) * 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor

Similar Documents

Publication Publication Date Title
Yan et al. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Dagar et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Yeku et al. Adoptive T-cell therapy for solid tumors
ES2968880T3 (es) Receptor de antígeno quimérico (CAR) que se une a BCMA, y usos del mismo
RU2770411C1 (ru) Химерные антигенные рецепторы m971
JP6420776B2 (ja) 免疫療法のためのエンゲージャー細胞
US9803021B2 (en) CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
JP2022545439A5 (cg-RX-API-DMAC7.html)
JP2023502503A5 (cg-RX-API-DMAC7.html)
Keler et al. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells
CN107523547A (zh) 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
WO2020224606A1 (zh) 靶向bcma的工程化免疫细胞及其用途
JP2024531446A5 (cg-RX-API-DMAC7.html)
JP2018523487A (ja) 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
CN114555791A (zh) Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
BR112020004212A2 (pt) conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos
Shang et al. VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity
BR112020004225A2 (pt) conjugados de fármaco de anticorpo anti-egfr (adc) e usos dos mesmos
JP2023512456A5 (cg-RX-API-DMAC7.html)
Lee et al. Antibody-based targeting of interferon-beta-1a mutein in HER2-positive cancer enhances antitumor effects through immune responses and direct cell killing
JP7232547B2 (ja) CDR1領域に突然変異したヒト化CD19 scFvを有するCAR-T細胞
WO2020160182A1 (en) Targeted delivery of ifn gamma using antibody fusion proteins
JP2025515324A5 (cg-RX-API-DMAC7.html)
JP2022526194A (ja) Flt3特異的キメラ抗原受容体およびその使用方法
Lu et al. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V